Sheng-li Xue, Md

This phase 2 trial tests the drug inotuzumab ozogamicin in 42 adults with B-cell acute lymphoblastic leukemia who have minimal residual disease (MRD) after a stem cell transplant. MRD means a few cancer cells remain undetectable by standard tests but can cause relapse. The drug a…

This study tests a combination of two drugs, venetoclax and azacitidine, for people newly diagnosed with a rare and hard-to-treat leukemia called acute leukemia of ambiguous lineage. The goal is to see if this treatment can help more patients achieve remission (cancer disappearan…